What Is Adipotide?

1. How does adipotide work?

White adipose tissue stores energy as fat. Like other living tissue, it needs a blood supply. In Kolonin and colleagues’ 2004 Nature Medicine study, researchers investigated whether directing a cell-killing peptide to fat’s blood vessels could reverse obesity in mice.

Adipotide combines a targeting sequence, CKGGRAKDC, with a cell-killing sequence written as D(KLAKLAK)₂. A short glycine linker joins them. The targeting part binds prohibitin exposed on the surface of cells lining adipose blood vessels. The second part disrupts mitochondrial membranes after entering susceptible cells, promoting apoptosis.

The intended result is loss of the vascular support that helps sustain white fat. “Fat-targeting” describes that design; it does not establish perfect selectivity in a human body. Prohibitin also has functions inside other cells, and tissue exposure determines which cells a drug can affect.

This mechanism also explains why adipotide belongs in a different discussion from AOD-9604, which researchers developed to investigate growth-hormone-related effects on fat metabolism. Sharing a fat-loss label does not make the molecules interchangeable.

2. What were the adipotide weight-loss results?

The best-known figures come from Barnhart and colleagues’ 2011 monkey study. Its fixed-dose experiment compared 10 treated obese rhesus monkeys with five saline controls over 28 treatment days and 28 recovery days.

Those measurements use different denominators and time points. A 38.7% relative reduction in body-fat percentage does not mean a loss of 38.7 percentage points. For example, a hypothetical decrease from 30% body fat to 20% is a 10-percentage-point drop and a 33.3% relative reduction.

Likewise, a change within the treated group includes everything that happened during treatment. It is not automatically the additional benefit over a control group. Quoting the largest number without its measurement, comparison and endpoint makes the result look more useful than it is.

None of these animal percentages supplies a human “pounds per month” estimate. The study population also differs from a lean lifter trying to reduce lower-belly fat while maintaining strength.

3. Does adipotide reduce appetite or improve insulin sensitivity?

The claim that adipotide produces fat loss while leaving appetite untouched is disputed. In a 2012 published comment, Leoluca Criscione questioned whether the monkey findings could reflect a direct effect on food consumption. The PubMed record also lists an author reply. The critique raises a competing explanation; it does not by itself settle the mechanism.

Kim and colleagues’ 2012 Diabetes paper investigated the peptide in obese mice and reported rapid improvement in glucose tolerance independent of weight loss and food intake. Glucose tolerance describes how the body handles a glucose challenge. It is a metabolic outcome, separate from visible fat loss or exercise performance.

Together, these studies justify asking how adipose blood vessels, feeding and glucose regulation interact. They cannot establish that adipotide will preserve a person’s appetite during a cut or treat their insulin resistance. Those claims require human outcomes, including comparison against existing treatment.

4. What happened to the human adipotide trial?

The ClinicalTrials.gov record, NCT01262664, uses the name PROHIBITIN-TP01. Searching only for “adipotide” can miss it.

MD Anderson registered a Phase 1 study in men with metastatic prostate cancer and obesity. Researchers wanted to identify the highest tolerable dose and assess safety. The rationale included investigating whether reducing white fat could affect prostate cancer biology. It was a cancer study in a selected patient population, so even a successful result would need further research before being applied to healthy people cutting body fat.

As checked on September 21, 2026, the registry reports four actual participants, a terminated status and no posted results. It lists January 2, 2019 as the completion date and gives the stopping reason as “Terminated per PI’s request.” PI means principal investigator.

The registry does not say that kidney injury caused termination. It also does not provide results demonstrating safety, weight loss or anticancer benefit. The literature search for this guide identified no published human efficacy report that fills that gap. A registered protocol describes what researchers intended to do; it cannot stand in for the missing outcomes.

5. Adipotide side effects and kidney damage

The primate paper documented changes in creatinine, urinary glucose and urinary protein, alongside kidney-tubule injury on tissue examination. Most laboratory changes reversed after withdrawal, although residual abnormalities remained in some animals at follow-up.

Kidney tubules help recover useful substances from filtered fluid. Injury there is a different issue from whether a compound causes nausea or an uncomfortable injection. Describing an animal finding as reversible does not establish that every person would recover, or that repeated exposure would be safe.

There is no dependable human denominator for an adipotide side-effect rate. Four enrolled participants with no posted outcomes cannot tell a reader whether an adverse effect occurs in one person out of ten or one out of a thousand. Online accounts can raise concerns, but they rarely establish product identity, dose accuracy or the contribution of other drugs.

A purity report also cannot resolve toxicity intrinsic to the molecule. Even correctly identified adipotide would still need human safety evidence. Nor has the research reviewed here established that hydration, supplements or a second peptide prevent its kidney effects.

6. Adipotide dosage, cycles and half-life

No safe and effective human fat-loss dose has been established. The Phase 1 protocol planned daily subcutaneous administration for 28 days and blood sampling to study pharmacokinetics, meaning how drug concentrations change in the body. Results were not posted.

That schedule cannot establish a half-life. Researchers choose trial schedules for several reasons, and the interval between injections is not a measurement of drug elimination. The sources reviewed here do not provide a dependable human half-life from which to build a dosing calendar.

Animal milligrams per kilogram cannot be turned into a validated human cycle by multiplying by body weight. Even a formal species-scaling calculation would leave tissue exposure and a safe therapeutic range unresolved. Reducing an unvalidated dose does not reveal whether it retains a benefit or avoids harm.

There is also no established maintenance protocol, cycle length or washout period for body recomposition. A reconstitution calculator can perform concentration arithmetic; it cannot supply any of those missing clinical findings.

7. Permanent fat loss, belly fat and muscle preservation

“Kills fat cells permanently” makes several claims at once: which cells are affected, whether the loss persists, and whether body fat can return. Adipotide’s proposed vascular mechanism does not answer all three. In the monkey study, weight and waist reductions began to reverse after treatment stopped.

Spot reduction needs its own evidence. Injecting near the abdomen does not demonstrate selective removal of fat at that location. The human record does not establish treatment of love handles, lipomas or a specific visceral-fat depot.

Muscle preservation is another unanswered question. A useful bodybuilding study would measure lean mass and strength during a controlled calorie deficit, with comparable protein intake and training. A lower body weight alone cannot establish a better physique or preserved performance.

Before-and-after photographs cannot separate adipotide’s contribution from simultaneous changes in diet, training, other compounds or hydration. For a reader evaluating a claimed result, starting body composition, elapsed time and measurement method are more informative than the photograph’s caption.

8. Adipotide vs AOD-9604, tesamorelin and GLP-1 drugs

There is no head-to-head human trial here that lets you rank adipotide against these drugs. Comparing a short monkey experiment with a months-long human obesity trial would mix species, populations, durations and outcomes.

The reviewed literature also does not establish added benefit or safety from stacking adipotide with semaglutide, tirzepatide or retatrutide. A different proposed mechanism makes a combination testable; it does not show that the combination works.

9. Which adipotide papers are worth reading?

The research includes discovery work, animal outcomes, a mechanistic critique and a human registry entry. These are different kinds of evidence.

The Hossen paper is useful when a product page cites newer delivery research as evidence for ordinary adipotide. Its nanoparticle formulation and the peptide bioconjugate are distinct interventions. A benefit from one cannot automatically be assigned to the other.

The next evidence that would change a human assessment is a reported clinical study: a verified formulation, a defined patient population, measured fat and lean mass, kidney outcomes and follow-up after withdrawal. The existing human registry entry still has no results posted.

10. Adipotide FAQ

• What is adipotide used for?

  Adipotide is a research compound studied for reducing white fat by targeting its blood supply. Animal studies explored obesity and glucose metabolism; a small human trial studied patients with metastatic prostate cancer and obesity. It has no FDA-approved use.

• Is FTPP the same as adipotide?

  FTPP, commonly expanded as fat-targeting proapoptotic peptide, is a name used for adipotide. The human trial used PROHIBITIN-TP01, or prohibitin-targeting peptide 1. A seller's name alone does not verify a vial's contents.

• Does adipotide work in humans?

  Human fat-loss efficacy has not been established. The registered Phase 1 trial enrolled four participants, was terminated and has no posted results. The frequently quoted weight-loss percentages come from monkeys.

• Does adipotide cause kidney damage?

  Kidney injury was documented in animal research, including changes in blood and urine measurements and kidney-tubule damage. The available human record cannot establish the frequency, severity or reversibility of this risk in people.

• Does adipotide permanently destroy fat cells?

  Permanent fat removal has not been established in people. Its proposed mechanism targets the blood vessels supplying white fat. Weight and waist measurements began to rebound after treatment stopped in the monkey study.

• What is a safe adipotide dosage?

  There is no established safe and effective human fat-loss dose. Animal doses and a dose-escalation trial's starting amount cannot validate a self-directed cycle, injection schedule or maintenance regimen.

• What is adipotide's half-life?

  The sources reviewed here do not establish a dependable human elimination half-life. The registered trial planned pharmacokinetic sampling but has no posted results. Its injection schedule cannot be used to calculate a half-life.

• Can adipotide be stacked with tirzepatide or semaglutide?

  No controlled human combination study was identified in this review. Different mechanisms do not establish extra fat loss, muscle preservation or safety from combining adipotide with either drug.

11. Sources